Palantir Patient Data Tech Rejected by Many NHS Trusts in England 2026

Palantir patient data technology has been rejected by many NHS trusts in England, according to freedom of information responses that reveal widespread dissatisfaction with the £330m federated data platform (FDP). The controversial US company's system, intended to integrate health data and improve efficiency, is facing pushback from organisations caring for millions of patients.

NHS Trusts Reject Palantir's Federated Data Platform

Freedom of information responses show that NHS organisations across England are declining to use Palantir's patient data technology, with some citing better or equal alternatives. While a few health bodies reported benefits such as easier waiting list management and improved surgery scheduling, many others have either declined to adopt the system or trialled it and reverted to old systems.

For example, a Suffolk trust stated that other systems "supercede" the FDP's functionality, while Greater Manchester's care board described the Palantir system as "duplicative" and "retrograde." These responses highlight a growing divide in the NHS over the value of the controversial contract.

Mixed Reactions from NHS Organisations

The feedback from NHS trusts is far from uniform. Some organisations have found the FDP useful for managing waiting lists and scheduling surgeries, but others see it as an unnecessary layer that duplicates existing capabilities. This mixed reaction raises questions about the £330m investment and whether the system can deliver on its promises.

Critics also point to Palantir's other contracts, including with the Israeli military and Donald Trump's homeland security forces, as reasons for concern. Additionally, there is public unease about the involvement of a company co-founded by tech billionaire Peter Thiel, who previously said, "The NHS makes people sick."

Data and Evidence: Comparing Palantir FDP to Alternatives

To understand the scale of rejection, consider the following comparison based on FOI responses from over two dozen trusts:

This table illustrates that while some trusts see value, many believe they can achieve similar or better results with existing or alternative systems.

Key Takeaways

• Many NHS trusts in England are rejecting Palantir's patient data technology, citing better alternatives.
• The £330m FDP contract is under scrutiny as trusts report mixed results.
• Concerns about Palantir's other contracts and public image add to the controversy.
• A break clause in the seven-year deal may be exercised amid growing opposition.

The Future of the NHS-Palantir Deal

With Andy Burnham's government facing a crunch decision on whether to exercise a break clause in the seven-year NHS-Palantir deal, the pressure is mounting. The contract was intended to better integrate health data to improve clinical accuracy and efficiency, but the rejection by many trusts suggests the system may not be delivering as hoped.

As the debate continues, the NHS must weigh the potential benefits of the FDP against the costs and the availability of alternative solutions. The outcome will have significant implications for how patient data is managed in England's healthcare system.

FAQ